The Future of Genomic Medicine
Robert F. Booth Ph.D., Celera Genomics - Bio
Functional Biology for Preclinical Profiling and Biomarker Identification
Magda Morton, Johnson & Johnson
Cytoskeletal Drug Discovery Technologies: Multi-Protein Biochemical Screens and Image-Based Cell Assays
Jeffrey T. Finer, MD PhD, Cytokinetics Inc. - Bio
Strategies for Rapid Target Validation in Malaria
R. Kip Guy, PhD, QB3, University of California, San Francisco - Bio
Optimizing Drug Discovery Efficiency by Target and Therapeutic Area Focus
Alex L. Harris PhD, Chiron Biopharmaceutical Research - Bio
Keynote:
The NIH Chemical Genomics Center: Opening a New Path to Discovery
James Inglese, PhD, NIH Chemical Genomics Center - Bio
Comprehensive Phenotyping and Biomarker Discovery
Aaron B. Kantor, PhD, SurroMed Inc.
Evolution of GPCR Screening at Roche
Dr. Bruce Koch, Roche Palo Alto - Bio
Engineering Therapeutic Antibodies
Henry B. Lowman, PhD, Genentech Inc.
Discovery of Novel Small Molecule Blockers of T-type Calcium Channels
Joseph McGivern PhD, Amgen Inc. - Bio
Protein Biomarker Discovery and Assays for Drug Development
William E. Rich, PhD, Ciphergen Biosystems Inc. - Bio
High-Throughput and High-Content Screening in Academia
David E. Solow-Cordero, PhD, High-Throughput Bioscience Center, Stanford University - Bio
Screening Assays for Scaffold-Based Drug Discovery: The Development of B-RafV599E Inhibitors
James Tsai, PhD, Plexxikon Inc.